HIV-associated lipodystrophy syndrome

Highly active antiretroviral therapy (HAART) for human immunodeficiency vir us-1 (HIV-1) and prophylactic therapy for opportunistic infections have inc reased survival. Adverse effects of HAART include lipid profile alterations , diabetes mellitus, and fat redistribution. These metabolic and physical c hanges are called the HIV-associated lipodystrophy syndrome. A link to prot ease inhibitors has been suggested, and more recently to nucleoside reverse transcriptase inhibitors and factors related to duration of HIV-1 infectio n itself.